摘要
目的探讨胰岛素强化序贯利拉鲁肽治疗2型糖尿病伴有肥胖症状患者的临床疗效。方法回顾性分析2017年1月至2019年12月江苏省中医院内分泌科收治的80例2型糖尿病合并肥胖患者的临床资料,按治疗方法不同分为2组,每组40例,对照组给予胰岛素强化治疗联合二甲双胍序贯甘精胰岛素治疗,利拉鲁肽组给予胰岛素强化治疗联合二甲双胍序贯利拉鲁肽治疗,疗程12周。对比分析2组患者治疗前后的体重指数(BMI)、血糖相关指标(FPG、2hPG、HbAlc)、血脂相关指标(TC、TG、HDL-C、LDL-C)、炎症相关指标(IL-6、TNF-α)水平的变化情况。结果治疗前,2组BMI、血糖相关指标、血脂相关指标、炎症相关指标相比较,差异均无统计学意义(P>0.05)。治疗后,利拉鲁肽组BMI[(26.40±1.60)kg/m^(2)]、FPG[(6.95±0.82)mmol/L]、2hPG[(7.49±0.95)mmol/L]、HbA1c[(7.02±0.82)%]水平低于对照组[(28.7±1.9)kg/m^(2)、(7.02±1.01)mmol/L、(8.92±1.01)mmol/L、(7.56±0.84)%];TC[(4.60±1.09)mmol/L]、TG[(0.90±0.79)mmol/L]、HDL-C[(1.60±0.24)mmol/L]、LDL-C[(2.60±0.78)mmol/L]水平低于对照组[(6.10±0.96)mmol/L、(1.50±0.57)mmol/L、(1.30±0.32)mmol/L、(3.00±0.45)mmol/L];IL-6[(9.64±1.05)ng/L]、TNF-α[(28.85±5.32)ng/L]水平低于对照组[(12.34±1.83)ng/L、(36.08±5.17)ng/L],差异均有统计学意义(P<0.01)。结论胰岛素强化序贯利拉鲁肽治疗2型糖尿病合并肥胖患者能够有效地控制血糖、体重,改善血脂代谢,减轻炎性反应,具有较高的临床应用价值。
Objective To investigate the clinical effect of insulin-enhanced sequentiallalutide in the treatment of type 2 diabetes mellitus with obesity.Methods The clinical data of 80 patients with type 2 diabetes and obesity were retrospectively analyzed.They were divided into two groups according to different treatment methods,each with 40 cases.The control group had glargine therapy after intensive insulin therapy combined with metformin,and the observation had liraglutide therapy after intensive insulin therapy combined with metformin for 12 weeks.The indexes of BMI,FPG,2hPG,HbAlc,TC,TG,HDL-C,LDL-C,IL-6,TNF-αwere analyzed.Results Before treatment,there were no statistically significant differences of BMI,FPG,2hPG,HbAlc,TC,TG,HDL-C,LDL-C,IL-6,TNF-αbetween the two groups(P>0.05).After treatment,BMI[(26.40±1.60)kg/m^(2)],FPG[(6.95±0.82)mmol/L],2hPG[(7.49±0.95)mmol/L],HbA1c[(7.02±0.82)%]were lower in the observation group than that in the control group[(28.70±1.90)kg/m^(2),(7.02±1.01)mmol/L,(8.92±1.01)mmol/L,(7.56±0.84)%].TC[(4.60±1.09)mmol/L],TG[(0.90±0.79)mmol/L],HDL-C[(1.60±0.24)mmol/L],LDL-C[(2.60±0.78)mmol/L]were lower in the observation group than that in the control group[(6.10±0.96)mmol/L,(1.50±0.57)mmol/L,(1.30±0.32)mmol/L,(3.00±0.45)mmol/L].IL-6[(9.64±1.05)ng/L],TNF-α[(28.85±5.32)ng/L]were lower in the observation group than that in the control group[(12.34±1.83)ng/L,(36.08±5.17)ng/L](P<0.01).Conclusion Liraglutide treatment after intensive glycemic control with insulin therapy for patients with type 2 diabetes and obesity is effective in controlling blood sugar,lowering body weight,regulating blood lipid metabolism,reducing inflammatory response,which has high value of clinical application.
作者
阮园
查敏
叶丽芳
张舒
贾佳
王丽娟
徐巍龙
周静波
余旭
余江毅
RUAN Yuan;ZHA Min;YE Li-fang;ZHANG Shu;JIA Jia;WANG Li-juan;XU Wei-long;ZHOU Jing-bo;YU Xu;YU Jiang-yi(Department of Endocrinology,Affiliated Hospital of Nanjing University of Chinese Medicine/Jiangsu Province Hospital of TCM,Nanjing 210029,Jiangsu,China)
出处
《东南国防医药》
2021年第2期122-125,共4页
Military Medical Journal of Southeast China
基金
国家自然科学基金(81704022)
江苏省第十四批“六大人才高峰”高层次人才选拔培养项目(WSN-088)。
